Webinars & Presentations

Learn about recent breakthroughs in treating blood disorders including sickle cell disease and immune deficiencies with cutting-edge CRISPR and Cas9 technologies.

Listen to this webinar hosted by Cell and Gene Therapy Insights about the latest advancements in cell therapy, specifically using homology-independent targeted insertion of a therapeutically relevant GD2-CAR transgene into the T cell receptor alpha constant (TRAC) locus using nanoplasmid DNA and CRISPR/Cas9 in primary human T cells.

In this enlightening breakout session from The State of CRISPR and Gene Editing summit hosted by Genetic Engineering and Biotechnology News, James Brady, PhD, presents Translating CRISPR-based Therapies to the Clinic with GMP-compliant, Scalable Electroporation.

Two UCLA scientists present their research on gene editing technologies to treat monogenic blood cell diseases at the 2024 ISCT annual meeting. Most human genetic diseases have heterogeneous mutations across the affected gene in different patients. We are approaching two primary immune deficiencies, X-linked Hyper IgM Syndrome and X-linked Agammaglobulinemia, using Cas9-mediated, site-specific insertion of minigene cDNA cassettes into the 5’ end of their respective genes (CD40L and BTK).

Our MaxCyte scientist, Isabel Daher, presents her poster from the 2024 American Society of Gene and Cell Therapy annual meeting. In this study, we utilized the MaxCyte ExPERT GTx, a cGMP-compliant electroporation instrument, to manufacture virus-like particles—packaged with CRISPR-Cas9 RNPs for genome editing in target cells—in adherent and suspension HEK293 cells.

Our MaxCyte scientist, Isabel Daher, presents her poster from the 2024 European Society of Gene and Cell Therapy annual meeting. MaxCyte’s electroporation platform efficiently produces high-potency VLPs, outperforms chemical transfection, and is scalable for clinical and commercial manufacturing.

KSQ Therapeutics shares their presentation on developing a scalable cGMP process for their engineered tumor-infiltrating lymphocyte (eTIL™) cell therapy.

Our MaxCyte scientist, Lauren Unsworth, presents her poster from the 2024 American Society of Gene and Cell Therapy annual meeting. In this study, we optimized conditions for electroporating primary NK cells with the GMP-compliant MaxCyte ExPERT GTx electroporation platform, with specific focus on maximizing cell viability, cell recovery, transfection efficiency, cell expansion and functionality.

In this GEN webinar, Dr. Alfred George discusses an electroporation approach that addresses efficiency challenges and engineers target cells at unprecedented scale. He also discusses MaxCyte electroporation and how it was used to express human ion channel variants in cultured mammalian cells to enable high throughput automated patch clamp recording. The MaxCyte STx enabled functional evaluation of ion channel variants without requiring stable cell line creation. You’ll learn how to use electroporation to create or correct mutations in induced pluripotent stem cells (iPSCs) for modeling human genetic diseases and providing proof of concept for gene therapy.

Key case studies are presented by Dr. Hyatt Want at Stanford University (Crystal Mackall & Steve Feldman Labs), Dr. Elena Stoyanova at Touchlight Genetics, and Dr. Marianna Romito at MaxCyte. Each presenter shares data on how to increase engineering efficiency in primary and stem cells, all while maintaining high cell viability and recovery for applications in gene editing and autologous/allogeneic cell therapy.